KaloBios CEO to Present at the International Society for Neglected Tropical Diseases Conference
(Thomson Reuters ONE) -
BRISBANE, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals,
Inc. (OTC:KBIOQ), a development stage biopharmaceutical company focused on
advancing treatments for neglected diseases, today announced that Cameron
Durrant, MD, chairman and CEO, will present how the company's Responsible
Pricing Model can make a transformative impact, during the International Society
for Neglected Tropical Diseases Diagnostics, Drug Discovery & Development
Conference in London, UK, May 25-26, 2016.
Dr. Durrant will also participate in a separate panel discussion on treatments
for Chagas disease alongside significant global leaders in neglected disease
research. KaloBios is working to advance benznidazole for potential US approval
to treat Chagas disease and to improve access to this essential medicine.
"We are committed to helping shape transformational change in the world of
medicines, with our Responsible Pricing Model as just the beginning," said Dr.
Durrant. "We seek to encourage and engage in open-minded dialogue with
stakeholders and are grateful to be part of the ISNTD effort to address critical
issues in neglected tropical diseases."
Details of the presentation and discussion panel are as follows:
Title: Pricing & incentivisation blueprints for the future
Date: Wednesday, May 25, 2016, 10:30 a.m. BST
Participants: Dr. Cameron Durrant, KaloBios Pharmaceuticals; Dr. Laura
Fregonese, European Medicines Agency
Title: Chagas disease and strategies for disease-specific treatments
Date: Wednesday, May 25, 2016, 3:45 p.m. BST
Participants: Dr. Eric Chatelain, DNDi; Pr. Simon Croft, London School of
Hygiene & Tropical Medicine; Dr. Brigitte Dacosta, bioMérieux; Dr. Julio Martin,
GSK; Dr. Cameron Durrant, KaloBios Pharmaceuticals
Chair: Roxanne Khamsi, Nature Medicine
For more information on the conference, please visit www.isntdd3.com.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIOQ) is a developmental stage,
biopharmaceutical company focused on advancing treatments for neglected
diseases. On Dec. 29, 2015, KaloBios filed a voluntary petition for bankruptcy
protection under Chapter 11 of Title 11 of the United States Bankruptcy Code,
and currently manages and operates its business and assets as a "debtor-in-
possession." KaloBios is working to emerge from bankruptcy.
Forward-Looking Statements
This release contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements reflect management's current knowledge, assumptions,
judgment and expectations regarding future performance or events. Although
management believes that the expectations reflected in such statements are
reasonable, they give no assurance that such expectations will prove to be
correct and you should be aware that actual results could differ materially from
those contained in the forward-looking statements. Forward-looking statements
are subject to a number of risks and uncertainties including, but not limited
to, Bankruptcy Court approval for the Company to continue its operations; the
Company's ability to manage expenses and fund its working capital needs during
the Chapter 11 process; the Company's ability to manage its relationships with
its creditors, vendors, and customers during the Chapter 11 process; the
Company's ability to emerge from bankruptcy successfully; the Company's access
to limited cash reserves and its ability to obtain additional capital on
acceptable terms, or at all, including the additional capital which will be
necessary to complete the clinical trials that the Company has initiated or
plans to initiate; the potential timing and outcomes of clinical studies of
benznidazole, lenzilumab, KB004 or any other products undertaken now or in the
future; the Company's ability to consummate the acquisition of rights to
benznidazole; the commercial viability of the Company's proposed drug pricing
program; the ability of the Company to timely source adequate supply of its
development products from third party manufacturers on whom the Company depends;
the potential, if any, for future development of any of its present or future
products; the Company's ability to successfully progress, partner or complete
further development of its programs; the uncertainties inherent in clinical
testing; the timing, cost and uncertainty of obtaining regulatory approvals; the
Company's ability to protect the Company's intellectual property; competition;
changes in the regulatory landscape or the imposition of regulations that affect
the Company's products; and other factors listed under "Risk Factors" in the
Company's most recent quarterly report on Form 10-Q filed with the Securities
and Exchange Commission on August 10, 2015, the Annual Report on Form 10-K filed
on March 16, 2015, and the Company's other filings with the Securities and
Exchange Commission.
All forward-looking statements are expressly qualified in their entirety by this
cautionary notice. You are cautioned not to place undue reliance on any forward-
looking statements, which speak only as of the date of this release. The company
has no obligation, and expressly disclaims any obligation to update, revise or
correct any of the forward-looking statements, whether as a result of new
information, future events or otherwise.
Media Contact:
Lisa Guiterman
(202) 330-3431 (cell)
(301) 217-9353 (office)
media(at)kalobios.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: KaloBios Pharmaceuticals Inc. via GlobeNewswire
[HUG#2015227]
Unternehmensinformation / Kurzprofil:
Datum: 25.05.2016 - 09:00 Uhr
Sprache: Deutsch
News-ID 473444
Anzahl Zeichen: 6623
contact information:
Town:
Brisbane
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 180 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"KaloBios CEO to Present at the International Society for Neglected Tropical Diseases Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
KaloBios Pharmaceuticals Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
